JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2022, 71(6):239-244 | DOI: 10.5817/CSF2022-6-239

The efficacy of triazavirin (riamilovir)-based treatment for coronavirus disease 2019 (COVID-19) in clinical trials and preliminary practical experiences

Ivan Malík1,2,*, Gustáv Kováč2, Lucia Hudecová2
1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University Bratislava, Slovak Republic
2 Institute of Chemistry, Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Slovak Medical University in Bratislava, Slovak Republic

Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has plagued the human population as 2019 turned into 2020, when first cases were confirmed to be infected with the pathogen in Wuhan City, the largest mega-city and capital of Hubei Province in Central China. Since this time, many pharmacotherapeutic modalities were suggested and used to treat the patients suffering from COVID-19.

Triazavirin (TZV; riamilovir) is a synthetic non-toxic broad-spectrum antiviral drug belonging into an

azolotriazine class. Several hypotheses and suggestions based on the knowledge about morphology, structure of virion, genome, replication cycle and functions of particular proteins within SARS-CoV-2 as well as in silico analyzes were published aiming to employ

TZV for the treatment of COVID-19. Results and conclusions from a well-known randomized controlled trial registered under the Registration No. ChiCTR2000030001, which was carried out in China in 2020, indicated not only the anti-SARS-CoV-2 efficacy of given aza analogue of

guanine but also some limitations of these outcomes in the context of their general interpretability and applicability. Thus, a primary aim of this review article was to provide more complex view on pharmacotherapeutic interventions based on

TZV against COVID-19/SARS-CoV-2. The focus was on relevant results and conclusions from clinical trials as well as practical experiences with given antiviral agent considering not only real benefits of chosen therapeutic strategies but also several obstacles connected with them.

Keywords: clinical trials; SARS-CoV-2; COVID-19; triazavirin; riamilovir; practical experiences

Received: September 19, 2022; Accepted: November 4, 2022; Published: June 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malík I, Kováč G, Hudecová L. The efficacy of triazavirin (riamilovir)-based treatment for coronavirus disease 2019 (COVID-19) in clinical trials and preliminary practical experiences. Čes. slov. farm. 2022;71(6):239-244. doi: 10.5817/CSF2022-6-239.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Artem'ev G. A., Rusinov V. L., Kopchuk D. S., Savchuk M. I., Santra S., Ulomsky E. N., Zyryanov G. V., Majee A., Du W., Charushin V. N., Chupakhin O. N. Synthetic approaches to 1,2,4-triazolo[5,1-c][1,2,4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir (Triazavirin®) active against SARS-CoV-2 (COVID-19). Org. Biomol. Chem. 2022; 20, 1828-1837. doi: 10.1039/d1ob02125g. Go to original source... Go to PubMed...
    2. Charushin V. N., Rusinov V. L., Varaksin M. V., Chupakhin O. N., Kovtun O. P., Spasov A. A. Development of drugs with direct antiviral action based on azaheterocyclic systems. Her. Russ. Acad. Sci. 2022; 92, 505-510. doi: 10.1134/S1019331622040104. Go to original source... Go to PubMed...
    3. Voinkov E. K., Drokin R. A., Ulomskiy E. N., Slepukhin P. A., Rusinov V. L., Chupakhin O. N. Crystal structure of medicinal product triazavirin. J. Chem. Crystallogr. 2019; 49, 213-218. doi: 10.1007/s10870-018-0750-2. Go to original source...
    4. Malík I., Čižmárik J., Pecháčová M., Kováč G., Hudecová L. Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Čes. slov. Farm. 2021; 70, 18-25. doi: 10.5817/CSF2021-1-18. Go to original source...
    5. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., Zhou H., Hu Zh., Zhou W., Zhao L., Chen J., Meng Y., Wang J., Lin Y., Yuan J., Xie Zh., Ma J., Liu W. J., Wang D., Xu W., Holmes E. C., Gao G. F., Wu G., Chen W., Shi W., Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395, 565-574. doi: 10.1016/S0140-6736(20)30251-8. Go to original source... Go to PubMed...
    6. Hu B., Guo H., Zhou P., Shi Zh.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021; 19, 141-154. doi: 10.1038/s41579-020-00459-7. Go to original source... Go to PubMed...
    7. Gaisenok O. V. The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis (In Russian). Vopr. Virusol. (Problems of Virology) 2020; 65, 167-175. doi: 10.36233/0507-4088-2020-65-3-167-175. Go to original source... Go to PubMed...
    8. My T. Th. A., Hieu L. T., Hai N. Th. Th., Loan H. Th. Ph., Bui Th. Q., Thuy B. Th. Ph., Trung Ph. V., Tram B. Th. B., Tran N. H. N., Quy Ph. T., Quang D. T., Oanh D. Th. Y., Tat Ph. V., Dao D. Q., Nhung N. Th. A. Study on SARS-CoV-2 inhibition of some potential drugs using molecular docking simulation. Vietnam J. Chem. 2020; 58, 666-674. doi: 10.1002/vjch.202000076. Go to original source...
    9. Sengupta A., Vijayaraghavan P., Srivastava P., Gupta L., Chandwani Ch., Narad P. In-silico structure-based drug discovery of candidate drugs against novel protein receptor complex nsp10-nsp16 of SARS-CoV-2 using drug repurposing approach. Coronaviruses 2021; 2, 255-264. doi: 10.2174/2666796701999201014161604. Go to original source...
    10. Ibrahim M. A. A., Abdelrahman A. H. M., Allemailem Kh. S., Almatroudi A., Moustafa M. F., Hegazy M.-E. F. In silico evaluation of prospective anti-COVID-19 drug candidates as potential SARS-CoV-2 main protease inhibitors. Protein J. 2021; 40, 296-309. doi: 10.1007/s10930-020-09945-6. Go to original source... Go to PubMed...
    11. Ercan S., Çinar E. A molecular docking study of potential inhibitors and repurposed drugs against SARS-CoV-2 main protease enzyme. J. Indian Chem. Soc. 2021; 98, art. no. 100041 (10 pp.). doi: 10.1016/j.jics.2021.100041. Go to original source...
    12. Shahab S., Sheikhi M. Triazavirin - Potential inhibitor for 2019-nCoV coronavirus M protease: A DFT study. Curr. Mol. Med. 2021; 21, 645-654. doi: 10.2174/1566524020666200521075848. Go to original source... Go to PubMed...
    13. Singal A. G., Higgins P. D. R., Waljee A. K. A primer on effectiveness and efficacy trials. Clin. Transl. Gastroenterol. 2014; 5, art. no. e45 (4 pp.). doi: 10.1038/ctg.2013.13. Go to original source... Go to PubMed...
    14. National Library of Medicine/National Center for Biotechnology Information. https://beta.clinicaltrials. gov (5 September 2022).
    15. Chinese Clinical Trial Registry. http://www.chictr.org.cn/enIndex.aspx (5 September 2022).
    16. Wu X., Yu K., Wang Y., Xu W., Ma H., Hou Y., Li Y., Cai B., Zhu L., Zhang M., Hu X., Gao J., Wang Y., Quin H., Wang W., Zhao M., Wu X., Zhang Y., Li L., Li K., Du Z., Mol B. W. J., Yang B. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing) 2020; 6, 1185-1191. doi: 10.1016/j.eng.2020.08.011. Go to original source... Go to PubMed...
    17. Wu X., Yu K., Wang Y., Xu W., Ma H., Hou Y., Li Y., Cai B., Zhu L., Zhang M., Hu X., Gao J., Wang Y., Qin H., Zhao M., Zhang Y., Li K., Du Z., Yang B. The efficacy and safety of triazavirin for COVID-19: A trial protocol. Engineering (Beijing) 2020; 6, 1199-1204. doi: 10.1016/j.eng.2020.06.011. Go to original source... Go to PubMed...
    18. Okoli G. N., Rabbani R., Al-Juboori A., Copstein L., Askin N., Abou-Setta A. M. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev. Anti Infect. Ther. 2022; 20, 267-278. doi: 10.1080/14787210.2021.1961579. Go to original source... Go to PubMed...
    19. Sabitov A. U., Belousov V. V., Edin A. S., Oleinichenko E. V., Gladunova E. P., Tikhonova E. P., Kuzmina T. Yu., Kalinina Yu. S., Sorokin P. V. Practical experience of using riamilovir in treatment of patients with moderate COVID-19 (In Russian). Antibiotiki i Khimioter. (Antibiotics and Chemotherapy) 2020; 65, 27-30. doi: 10.37489/0235W2990W2020W65W7W8W27W30. Go to original source...
    20. Sabitov A. U., Sorokin P. V., Dashutina S. Yu. The efficacy and safety of riamilovir in the treatment of patients with COVID-19 (In Russian). Antibiotiki i Khimioter. (Antibiotics and Chemotherapy) 2021; 66, 33-37. doi: 10.24411/0235-2990-2021-66-1-2-33-37. Go to original source...
    21. Kasyanenko K. V., Maltsev O. V., Kozlov K. V., Lapikov I. I., Lvov N. I., Sukachev V. S., Zhdanov K. V., Sorokin P. V., Ratnikova A. K. Clinical efficiency and safety of riamilovir for treating patients with SARS-CoV-2 infection (In Russian). Antibiotiki i Khimioter. (Antibiotics and Chemotherapy) 2020; 65, 16-21. doi: 10.37489/0235-2990-2020-65-11-12- 16-21. Go to original source...
    22. Kasyanenko K. V., Kozlov K. V., Maltsev O. V., Lapikov I. I., Gordienko V. V., Sharabhanov V. V., Sorokin P. V., Zhdanov K. V. Evaluation of the effectiveness of riamilovir in the complex therapy of patients with COVID-19 (In Russian). Ter. Arkh. (Therapeutic Archive) 2021; 93, 290-294. doi: 10.26442/00403660.2021.03.200 719. Go to original source... Go to PubMed...
    23. Sabitov A. U., Sorokin P. V., Dashutina S. Y. Experience of the preventive use of the drug riamilovir in the foci of coronavirus infection (COVID-19; In Russian). Ter. Arkh. (Therapeutic Archive) 2021; 93, 435-439. doi: 10.26442/00403660.2021.04.200751. Go to original source... Go to PubMed...
    24. Zhogolev S. D., Gorenchuk A. N., Zhogolev K. D., Kuzin A. A., Kulikov P. V., Kolesnikov V. V. The use of triazavirin for prevention COVID-19 and other acute respiratory diseases for young people (In Russian). Problemy Meditsinskoy Mikologii (Problems in Medical Mycology) 2022; 24, 72.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.